Maysa Vilbert
@MaysaVilbert
Followers
195
Following
416
Statuses
63
Oncologist passionate about enhancing the lives of cancer survivors, advancing cancer research, and investigating immune toxicities.
Cambridge, USA
Joined April 2021
RT @FunchainMD: Top of the irAE to you this Monday! 2 ASPirE events to kick off 2025: ASPirE Annual Meeting 2/28 - 3/1: in person think ta…
0
2
0
RT @metaacademy_ofc: From Rio de Janeiro to Boston, Cardiff to Kaliningrad, Recife to Madrid – this publication is a testament to the globa…
0
2
0
RT @DFCI_BreastOnc: Check out this new systematic review and meta-analysis discussing #AntibodyDrugConjugates in patients with advanced/met…
0
10
0
RT @DrBetofMDPhD: Always an inspiration to hear Dr Stephanie Goff present on #TILs. We need to stop thinking about this as palliative thera…
0
14
0
RT @JCOPO_ASCO: Safety and Efficacy of Osimertinib in Patients With NSCLC and Uncommon Tumoral Epidermal Growth Factor Receptor Mutations:…
0
3
0
0
0
1
RT @DVAraujoMD: 1/ I’m thrilled to share our study, “Low-Dose Anti-PD(L)1 for the Treatment of Solid Malignancies,” now published in @JCOGO…
0
18
0
RT @jpriantti: So proud to share our work in @JCOPO_ASCO 🫁Our meta-analysis highlights the safety and efficacy of #osimertinib in patients…
0
1
0
Congratulations @isabfmichelon and @m_dacoregio_!👏 These findings are important in understanding the impact of ADCs in #HER2-low #MBC. Honored to be part of it! Kudos to all the amazing collaborators and mentors @LudiCa19862,@jpriantti,@LucasVian2, @PTarantinoMD, @E_de_Azambuja
Proud to share our work in @TAMedOncol! Our meta-analysis of 2000+ patients with #HER2-low #MBC reveals a 50% reduction in the risk of progression/death with ADCs compared to chemo. #BCSM 🔗 full:
0
2
9
✨Our publication in JCOPO on the efficacy of osimertinib in rare EGFR NSCLC is out! Grateful to collaborate with such a talented team to improve patient care! @jpriantti,@waraonc23,@ACortelliniMD, @LudiCa19862 and many others! Thank you for the mentorship of @thenasheffect! 👏😃
🚨⭐️ effort led by @jonathanpriantti @waraonc23 @MaysaVilbert out now in @JCOPO_ASCO on Efficacy of osimertinib in rare EGFR NSCLC. @EGFRResisters. Most comprehensive systematic review to date! @AminNassarMD @ACortelliniMD @JairBar4 @Alfdoc2 @LudiCa19862
0
1
5
RT @thenasheffect: 🚨⭐️ effort led by @jonathanpriantti @waraonc23 @MaysaVilbert out now in @JCOPO_ASCO on Efficacy of osimertinib in rare E…
0
10
0
RT @Alfdoc2: @ACortelliniMD @thenasheffect @jpriantti @JCOPO_ASCO @waraonc23 @MaysaVilbert @AminNassarMD Kudos to all the authors! I’m trul…
0
2
0
RT @ACortelliniMD: Really nice bunch of people led by @thenasheffect and @jpriantti in this systematic review/metanalysis out on @JCOPO_ASC…
0
3
0
✨Our publication in JCOPO on the efficacy of osimertinib in rare EGFR NSCLC is out! Grateful to collaborate with such a talented team to improve patient care! @jpriantti, @waraonc23, @ACortelliniMD, @LudiCa19862 and many others! Thank you for the mentorship of @thenasheffect! 👏
It was really fun to be a part of this collaborative work putting a lot of data on the efficacy of osi on rare EGFR NSCLC. Special kudos to @jpriantti who made a huge effort on this project as well as superb supervision by @MaysaVilbert and @thenasheffect and many others!
0
1
10
Congratulations @buenaaziri!! Great work, well done!
Our findings suggest that treatment with new-generation BTKi is associated with a significant reduction in the risk of cardiac events, AF, and AF-related treatment discontinuation compared with the old-generation BTKi. #BTKi #Cardiotoxicity #CardioOncology #AHA24 @AHAScience
0
0
2
RT @CheckpointNowMD: Here is our next episode- Thought leaders in #irAE @kreynoldsMD @lexameara @EladSharonMD and CPN hosts @afreenshariffm…
0
2
0
0
0
0
RT @jpriantti: Just released! Our meta-analysis underscores the importance of increasing awareness about lorlatinib-related neurocognitive…
0
3
0
RT @isabfmichelon: Hot off the press! Our meta-analysis supports EGFR-TKI rechallenge as a valid strategy in metastatic #NSCLC. This may o…
0
6
0